US Supreme Court unanimously overturns Federal Circuit decision in Medtronic

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2025

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

US Supreme Court unanimously overturns Federal Circuit decision in Medtronic

The US Supreme Court has unanimously reversed the Federal Circuit decision in Medtronic v Boston Scientific, reinforcing the established rule that the patent owner bears the burden of proving that infringement has occurred

The ruling overturns a September 2012 decision by the Federal Circuit, which found that in cases where a licensee seeks a declaratory judgment against a patent holder, the licensee bears the burden of proof. The Federal Circuit reasoned that since Medtronic was asking a court to declare the products in question did not infringe, it should bear the burden of proving it was entitled to such relief.

But after hearing arguments in November last year, the Supreme Court unanimously ruled today that even in such cases, the patentee bears the burden of proof.

In its opinion, the Supreme Court quoted a decision in Precision Instrument Manufacturing v Automotive Maintenance Machin­ery: The public interest, of course, favours the maintenance of a well-functioning patent system. But the ‘public’ also has a ‘paramount interest in seeing that patent monopo­lies . . . are kept within their legitimate scope.'”

Justice Stephen Breyer, writing on behalf of all the justices, concluded: “The general public interest considerations are, at most, in balance. They do not favour a change in the ordinary rule imposing the burden of proving infringement upon the patentee.”

The dispute stems from 2007 claim that a device manufactured by Medtronic, known as a cardiac resynchronisation therapy, infringed patents owned by Mirowski Family Ventures, which licensed them to Boston Scientific. The parties had agreed that Medtronic would sub-license the patents and pay royalties on any new products it made which used the technology they covered.

But the parties disagreed on whether Medtronic’s CRT products used technology covered by the patents. The District Court for the District of Delaware found that the patents were valid and enforceable but that Medtronic did not violate them.

more from across site and SHARED ros bottom lb

More from across our site

A $110 million US verdict against Apple and an appellate order staying a $39 million trademark infringement finding against Amazon were also among the top talking points
Attorneys are watching how AI affects trademark registrations and whether a SCOTUS ruling from last year will have broader free speech implications
Patent lawyers explain why they will be keeping an eye on the implications of a pharma case and on changes at the USPTO in the second half of 2025
The insensitive reaction to a UK politician crying on TV proves we have a long way to go before we can say we are tackling workplace wellbeing
Adrian Percer says he was impressed by the firm’s work on billion-dollar cases as well as its culture
In our latest interview with women IP leaders, Catherine Bonner at Murgitroyd discusses technology, training, and teaching
Developments included an update in the VAR dispute between Ballinno and UEFA, the latest CMS updates, and a swathe of market moves
The LMG Life Sciences Americas Awards is thrilled to present the 2025 shortlist
A new order has brought the total security awarded to a Canadian tech company to $45 million, the highest-ever by an Indian court in an IP case
Andrew Blattman reflects on how IP practices have changed and shares his hopes for increased AI use and better performance on the stock market
Gift this article